Europe’s medicines regulator added a rare nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson’s Covid-19 vaccine after the European Medicines Agency reviewed 108 cases reported worldwide.

The U.S. Food and Drug Administration is planning a new warning for Johnson & Johnson’s Covid-19 vaccine over a rare but serious side effect, Guillain-Barré syndrome (GBS).

South San Francisco-based Annexon, focused on drugs for autoimmune and neurodegenerative disorders, closed on a $100 million Series C financing led by Redmile Group.